Day Three Labs has announced that it will be researching a remedy for Parkinson’s Disease using cannabis. The research and innovation will be funded by CanNegev, the world’s first government-sponsored cannabis innovation incubator.
“Research shows that cannabis has the ability to ease Parkinson’s symptoms in patients, but to date, no one has been able to decipher the exact combination of cannabinoids and terpenes for a consistent, reliable and repeatable remedy,” said Dr. Shimon Lecht, chief innovation officer at Day Three Labs. “There are over a trillion possible combinations of cannabinoids and terpenes that could be derived from the cannabis plant, but only a handful are the optimal combination to treat Parkinson’s. Our mission is to discover the correct combination, and to identify the precise ratio so all active ingredients interact in the right way with each other. We can then leverage our Unlokt technology to make a product that will deliver the precise combination of cannabinoids and terpenes to patients quickly, safely and effectively.”
For the first time ever, there is technology available that allows for delivery in a safe, controlled, precise and predictable way. Unlokt by Day Three Labs enables drug delivery that protects the cannabinoids and terpenes and allows the body to receive the intended medicinal effects, in the intended amount. Funding from CanNegev enables Day Three Labs to find the combination of cannabinoids that work best to treat Parkinson’s and use Unlokt to take the research straight from the lab to product development.
“Parkinson’s Disease and other neuro-degenerative diseases have been notoriously difficult to treat, and the pharmaceutical industry has failed to develop appropriate solutions to address these terrible diseases or alleviate symptoms,” said Ziv Bet Or, vice president of business development at CanNegev. “Our mission has been solely focused on funding tech-focused companies with proven innovation that has the potential to advance from the research stage to the drug development stage to address unmet needs. DTL shows the potential to identify a breakthrough therapeutic remedy for Parkinson’s Disease symptoms and a pathway for effective delivery of the treatment.”
DTL is the only company to have passed the first phase of the CanNegev program, solidifying the concept and building the project idea, and receive funding for the second phase to start research, data collection and presentation to The Office of the Chief Scientist of Israel, recently rebranded as the Israel Innovation Authority (IIA) in September 2022. The third and final phase of the program will require a presentation of the proof of concept to the IIA to secure additional funding of 1.25 million Israeli Shekels for product development, 70% of which is a government grant.
Day Three Labs is a cannabinoid CPG ingredient manufacturer specializing in the development and commercialization of novel cannabis product solutions. An international company with headquarters in Denver, and a pharmaceutical research lab in Israel, DTL reimagines existing cannabis offerings with pharmaceutical-grade technology and innovation like Unlokt to deliver precision and predictability to the infused product experience.
